Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRX-801 with Ultrasound in Acute Ischemic Stroke
NCT00504842Phase 2Terminated
- Sponsor
- ImaRx Therapeutics, Inc.
- Start
- Dec 2006
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial in ischemic stroke comparing MRX-801 + Ultrasound + tPA with Placebo + Ultrasound + tPA (2 arms). Primary endpoint: Incidence of symptomatic intracranial hemorrhage at 36 hours. Started Dec 2006; status: terminated.
02
Drugs
MRX-801
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00504842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00504842.